SGMO vs. ATAI

Last updated Apr 3, 2026

Compare and contrast key facts about Sangamo Therapeutics, Inc. (SGMO) and Atai Life Sciences N.V. (ATAI).

Performance

SGMO vs. ATAI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sangamo Therapeutics, Inc. (SGMO) and Atai Life Sciences N.V. (ATAI). The values are adjusted to include any dividend payments, if applicable.

SGMO vs. ATAI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
SGMO Sangamo Therapeutics, Inc.	-28.55%	-58.82%	87.74%	-82.70%	-58.13%	-33.86%
ATAI Atai Life Sciences N.V.	-7.33%	207.52%	-5.67%	-46.99%	-65.14%	-60.77%

Fundamentals

Market Cap SGMO : $101.35M ATAI : $1.19B
EPS SGMO : -$0.41 ATAI : -$2.72
PS Ratio SGMO : 2.27 ATAI : 225.06
Total Revenue (TTM) SGMO : $39.55M ATAI : $4.09M
Gross Profit (TTM) SGMO : $25.32M ATAI : $3.08M
EBITDA (TTM) SGMO : -$117.16M ATAI : -$113.05M

Returns By Period

In the year-to-date period, SGMO achieves a -28.55% return, which is significantly lower than ATAI's -7.33% return.

SGMO

• 1D: 15.38%
• 1M: -23.42%
• YTD: -28.55%
• 6M: -57.13%
• 1Y: -54.06%
• 3Y*: -44.23%
• 5Y*: -52.40%
• 10Y*: -26.26%

ATAI

• 1D: 2.43%
• 1M: 2.71%
• YTD: -7.33%
• 6M: -26.26%
• 1Y: 156.08%
• 3Y*: 25.88%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SGMO vs. ATAI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SGMO

SGMO Risk / Return Rank: 19
SGMO Sharpe Ratio Rank: 18
SGMO Sortino Ratio Rank: 23
SGMO Omega Ratio Rank: 23
SGMO Calmar Ratio Rank: 16
SGMO Martin Ratio Rank: 16

ATAI

ATAI Risk / Return Rank: 86
ATAI Sharpe Ratio Rank: 88
ATAI Sortino Ratio Rank: 86
ATAI Omega Ratio Rank: 82
ATAI Calmar Ratio Rank: 90
ATAI Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SGMO vs. ATAI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sangamo Therapeutics, Inc. (SGMO) and Atai Life Sciences N.V. (ATAI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SGMO	ATAI	Difference
Sharpe ratio Return per unit of total volatility	-0.50	1.90	-2.40
Sortino ratio Return per unit of downside risk	-0.24	2.62	-2.86
Omega ratio Gain probability vs. loss probability	0.97	1.32	-0.35
Calmar ratio Return relative to maximum drawdown	-0.68	4.28	-4.96
Martin ratio Return relative to average drawdown	-1.20	7.93	-9.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SGMO vs. ATAI - Sharpe Ratio Comparison

The current SGMO Sharpe Ratio is -0.50, which is lower than the ATAI Sharpe Ratio of 1.90. The chart below compares the historical Sharpe Ratios of SGMO and ATAI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SGMO	ATAI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.50	1.90	-2.40
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.49	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.28	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.16	-0.35	+0.19

Correlation

The correlation between SGMO and ATAI is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SGMO vs. ATAI - Dividend Comparison

Neither SGMO nor ATAI has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

SGMO vs. ATAI - Drawdown Comparison

The maximum SGMO drawdown since its inception was -99.50%, roughly equal to the maximum ATAI drawdown of -94.77%. Use the drawdown chart below to compare losses from any high point for SGMO and ATAI.

Drawdown Indicators

	SGMO	ATAI	Difference
Max Drawdown Largest peak-to-trough decline	-99.50%	-94.77%	-4.73%
Max Drawdown (1Y) Largest decline over 1 year	-69.70%	-48.06%	-21.64%
Max Drawdown (5Y) Largest decline over 5 years	-98.05%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-99.06%	—	—
Current Drawdown Current decline from peak	-99.40%	-80.95%	-18.45%
Average Drawdown Average peak-to-trough decline	-83.93%	-79.80%	-4.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	39.33%	25.92%	+13.41%

Volatility

SGMO vs. ATAI - Volatility Comparison

Sangamo Therapeutics, Inc. (SGMO) has a higher volatility of 32.61% compared to Atai Life Sciences N.V. (ATAI) at 21.33%. This indicates that SGMO's price experiences larger fluctuations and is considered to be riskier than ATAI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SGMO	ATAI	Difference
Volatility (1M) Calculated over the trailing 1-month period	32.61%	21.33%	+11.28%
Volatility (6M) Calculated over the trailing 6-month period	80.23%	53.33%	+26.90%
Volatility (1Y) Calculated over the trailing 1-year period	108.76%	84.82%	+23.94%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	106.69%	84.07%	+22.62%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	95.11%	84.07%	+11.04%

Financials